These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25688743)

  • 1. mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma.
    Scheller T; Hellerbrand C; Moser C; Schmidt K; Kroemer A; Brunner SM; Schlitt HJ; Geissler EK; Lang SA
    Br J Cancer; 2015 Mar; 112(5):841-50. PubMed ID: 25688743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice.
    Lang SA; Moser C; Fichnter-Feigl S; Schachtschneider P; Hellerbrand C; Schmitz V; Schlitt HJ; Geissler EK; Stoeltzing O
    Hepatology; 2009 Feb; 49(2):523-32. PubMed ID: 19085954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
    Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
    Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
    Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H; Zhang C; Chi H; Meng Z
    Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft.
    Jasinghe VJ; Xie Z; Zhou J; Khng J; Poon LF; Senthilnathan P; Glaser KB; Albert DH; Davidsen SK; Chen CS
    J Hepatol; 2008 Dec; 49(6):985-97. PubMed ID: 18930332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
    Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
    Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo.
    Boichuk S; Galembikova A; Dunaev P; Micheeva E; Valeeva E; Novikova M; Khromova N; Kopnin P
    Molecules; 2018 Oct; 23(10):. PubMed ID: 30326595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma.
    Le TBU; Vu TC; Ho RZW; Prawira A; Wang L; Goh BC; Huynh H
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
    Newell P; Toffanin S; Villanueva A; Chiang DY; Minguez B; Cabellos L; Savic R; Hoshida Y; Lim KH; Melgar-Lesmes P; Yea S; Peix J; Deniz K; Fiel MI; Thung S; Alsinet C; Tovar V; Mazzaferro V; Bruix J; Roayaie S; Schwartz M; Friedman SL; Llovet JM
    J Hepatol; 2009 Oct; 51(4):725-33. PubMed ID: 19665249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor.
    Prawira A; Le TBU; Ho RZW; Huynh H
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):2955-2968. PubMed ID: 34156519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
    Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
    Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
    Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
    Kim SH; Ryu H; Ock CY; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Bang SM; Kim JH; Lee JS; Ahn JB; Kim KJ; Rha SY
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
    Ou DL; Lee BS; Lin LI; Liou JY; Liao SC; Hsu C; Cheng AL
    Mol Cancer; 2014 Jan; 13():2. PubMed ID: 24387108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
    El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
    Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.